SCHEMBL532127

SCHEMBL532127

O=C1CCNC(C(=O)O)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.47
GRIA2 P42262 3/20 0.42
CYP2D6 P10635 3/20 0.37
ALOX15 P16050 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP2C19 P33261 3/20 0.37
LMNA P02545 2/20 0.37
BLM P54132 2/20 0.37
TSHR P16473 2/20 0.37
MEN1 O00255 2/20 0.37
THRB P10828 2/20 0.37
KMT2A Q03164 2/20 0.37
RAB9A P51151 1/20 0.37
PMP22 Q01453 1/20 0.37
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
ALDH1A1 P00352 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15606429 1.00 EGLN1 (0.47) EGLN1GRIA2CYP2D6ALOX15CYP1A2
SCHEMBL16967412 1.00 EGLN1 (0.47) EGLN1GRIA2CYP2D6ALOX15CYP1A2
Acetic Acid SCHEMBL28383924 0.94 EGLN1 (0.42) EGLN1GRIA2CYP2D6ALOX15CYP1A2
Acetic Acid SCHEMBL28383926 0.94 EGLN1 (0.42) EGLN1GRIA2CYP2D6ALOX15CYP1A2
Ethylene SCHEMBL16894867 0.79 LMNA (0.32) EGLN1GRIA2LMNA
SCHEMBL7422071 0.77
SCHEMBL190462 0.77
SCHEMBL190463 0.77
SCHEMBL1703167 0.77 EGLN1 (0.45) EGLN1GRIA2CYP2D6ALOX15CYP1A2
SCHEMBL5765192 0.77 EGLN1 (0.45) EGLN1GRIA2CYP2D6ALOX15CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440526-B1 3-HALO-6-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2014-11-12 EP claimed
CN-102459176-A 3-halo-(arly)-4-iminotetrahydropicolinates and their use as herbicides DOW AGROSCIENCES LLC (US) 2012-05-16 CN claimed
EP-2440526-A1 3-HALO-6-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES Dow AgroSciences LLC (US) 2012-04-18 EP claimed
WO-2010144379-A1 3-HALO-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2010-12-16 WO claimed
US-20100311594-A1 3-HALO-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2010-12-09 US claimed
EP-0633928-B1 MICRO-ORGANISMS, PREPARATION METHOD THEREFOR AND USES THEREOF AVENTIS PHARMA SA (FR) 2003-11-19 EP claimed
US-20030013616-A1 Method for manufacturing outsole for footwear without applying external mold rubricant onto mold, and formulating composition therefor PARK HEE-DAE (KR) 2003-01-16 US claimed
WO-2002049822-A1 METHOD FOR MANUFACTURING OUTSOLE FOR FOOTWEAR WITHOUT APPLYING EXTERNAL MOLD RUBRICANT ONTO MOLD, AND FORMULATING COMPOSITION THEREFOR YAGNICK METHA (US) 2002-06-27 WO claimed
CN-117659017-B TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2026-05-15 CN disclosed
US-12577258-B2 Macrocyclic compound VERNALIS (R&D) LIMITED (GB) 2026-03-17 US disclosed
US-12465660-B2 Compositions and methods for cancer imaging and radiotherapy VECT-HORUS (FR) 2025-11-11 US disclosed
EP-4223368-B1 MACROCYCLIC COMPOUNDS INCORPORATING PIPERIDINE AND QUINOLINE OR QUNAXOLINE AS IRAK-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS ASAHI KASEI PHARMA CORP (JP) 2025-05-21 EP disclosed
CN-116348472-B Macrocyclic compounds 旭化成制药株式会社 2024-12-03 CN disclosed
US-20240100204-A1 COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY VECT-HORUS (FR) 2024-03-28 US disclosed
CN-1152338-A Streptogramines and method for preparing same by mutasynthesis RHONE POULENC RORER SA (FR) 1997-06-18 CN disclosed
US-5610241-A Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers CORNELL RESEARCH FOUNDATION, INC. (US) 1997-03-11 US disclosed
WO-1996022775-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1996-08-01 WO disclosed
EP-0308983-A2 NMR imaging with Mn(II) coordination compositions SALUTAR, INC. (US) 1989-03-29 EP disclosed
US-4330548-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1982-05-18 US disclosed
US-4296113-A FOR TREATING HYPERTENSION BY INHIBITING ANGIOTENSIN CONVERTING ENZYME E. R. SQUIBB & SONS, INC. (US) 1981-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577258-B2 Macrocyclic compound IRAK1, IRAK4, IRAK2 EGLN1 1028/4885GRIA2 392/4885CYP2D6 3138/4885
US-20100311594-A1 3-HALO-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES HDHD5, ATL3, HCAR3 EGLN1 1294/4885GRIA2 1024/4885CYP2D6 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.